




MEDCAP

INVESTOR
IN LIFE SCIENCE

Company Presentation
2026

We create value in Life Science and contribute to improved quality of life



MedCap Snapshot

Q3 2025

Revenue,
LTM million SEK

1 991

EBITA margin
LTM

17%

Business Areas

Assistive
Tech



MedTech



Specialty
Pharma



Employees & locations

630



Strategy

Buy & Build

*A long-term home for
well run Life Science
companies*


EBITA CAGR
5 years

25%


MedCap | An active investor in Life Science companies

Last Twelve Months, Q3 2025

Sales by Business Area



Sales by Market



Our Model

Life Science

Sector focus
Network of expertise
Knowledge sharing
Market insight



Entrepreneurship

Decentralized & local responsibility
Integrity of acquired brands
Quick & agile, yet long-term mindset
Ambitious organic business plans



Group Scale

Scalable business areas
Merger & Acquisitions
Governance – ESG
Financing



MedCap Business Areas

Assistive Tech



Cognition, Alarms, Communication



Accessibility



Mobility



Orthopedic aids



Patient handling



Simplifying life for individuals with special needs

Med Tech



Diagnostic ECG



Digitalizing work-flow

Probiotics, Nutrition, Packaging



Contract manufacturing

Components for medical imaging



Carbon fiber CDMO

Ultra clean air for infection control



Cost effective air quality in OR

Specialty Pharma



Pharma



Nordic Sales, Pharma portfolio, Non-license

CDMO

Sterile & non-sterile liquid pharma production

Our business

Solid markets

Non-cyclical

Demographic drivers

Market niches

Market share potential

Understanding the eco-systems

Payor

Prescriber

End-user

Healthcare providers

Distribution

Regulation

Sales & Marketing

Product Development

Offering

Active ownership


People & Management

Business objectives

Performance management

Bolt-on acquisitions

How we grow our group



Companies in our subsidiaries' network
Active industry participation and search
Succession or next step situations
Structured sales processes

Investment strategy


Scope




What we look for



20 years of acquisitions



Sales and EBITA rolling 12 months by quarter



Excluding one-time effects

Financial Targets

